Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: GlobeNewswire
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC – Therapeutic areas outside of RAS-mutated mCRC – In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mCRC can be independent of RAS mutational status – – In SCLC and ovarian cancer, robust preclinical data underscore onvansertib’s activity in combination treatments across multiple tumors – SAN DIEGO, April 08, 2024 (GLOBE NEWS
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other Diseases [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateGlobeNewswire
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]Yahoo! Finance
- Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/2/23 - Beat
CRDF
Sec Filings
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- CRDF's page on the SEC website